Form 4: Pfizer Executive Christoffel Boshoff Acquires Stock Appreciation Rights

Christoffel Boshoff, President of R&D at Pfizer, acquired 495,765 stock appreciation rights (SARs) on March 4, 2025, which will be settled in Pfizer common stock on March 4, 2030, subject to vesting requirements.

Summary

• On March 4, 2025, Christoffel Boshoff, President of R&D at Pfizer, acquired 495,765 stock appreciation rights (SARs).
• These SARs have an exercise price of $25.75.
• The SARs will vest and be settled in shares of Pfizer common stock on March 4, 2030, which is the fifth anniversary of the grant date, subject to certain vesting requirements.
• Following the transaction, Boshoff directly owns 495,765 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of SARs by a key executive suggests confidence in the company's future, but the document itself is simply a regulatory filing of the transaction.

Positives

• The acquisition of stock appreciation rights by a high-ranking executive like the President of R&D could be interpreted as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting requirements associated with the stock appreciation rights introduce an element of uncertainty, as the actual value realized will depend on the executive's continued employment and the company's stock performance over the vesting period.

Future Outlook

The stock appreciation rights will be settled in shares of Pfizer common stock on March 4, 2030, subject to certain vesting requirements.

Industry Context

Stock appreciation rights are a common form of executive compensation in the pharmaceutical industry, aligning executive incentives with shareholder value by rewarding increases in the company's stock price.

Comparison to Industry Standards

• Companies like Johnson & Johnson (JNJ) and Merck (MRK) also utilize stock appreciation rights as part of their executive compensation packages.
• The specific terms and conditions of these SARs, such as the vesting schedule and exercise price, would need to be compared to industry benchmarks to assess their competitiveness and alignment with performance goals.

Stakeholder Impact

• The acquisition of stock appreciation rights by a key executive could positively influence shareholder sentiment, as it aligns the executive's interests with those of the shareholders.

Key Dates